Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms.
Alumis (NASDAQ:ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape
Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis.
Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week 24, approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100, benchmarks historically associated with injectable biologics rather than pills. Responses were rapid, separating from placebo on PASI 90 as early as Week 4, and durability improved over time.
Envudeucitinib also demonstrated superiority over apremilast across all PASI endpoints, while maintaining a favorable safety and tolerability profile consistent with prior studies. Alumis plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, positioning envudeucitinib as a potential best-in-class oral therapy in a market affecting more than 8 million adults in the U.S.
Kraig Biocraft Laboratories (OTCQB:KBLB): From Scientific Persistence to Commercial Inflection
Kraig Biocraft Laboratories continues to draw long-term investor attention as decades of genetic engineering and biomaterials research converge into a scalable commercial model. The company's recombinant spider silk platform, built on transgenic silkworms rather than fermentation or mammals, has moved decisively from theory to production.
Key developments include record-setting gene insertions, the rollout of BAM-1 and next-generation hybrids, and the launch of parallel manufacturing facilities across Southeast Asia. These advances have improved yield, resilience, and production continuity, enabling Kraig Labs to secure its first commercial trial orders and begin engaging customers in performance apparel, defense, and luxury materials.
With a growing production footprint and proprietary genetics that competitors failed to achieve despite massive capital outlays, Kraig Labs is increasingly viewed as a rare example of deep biotech innovation crossing into real-world industrial scalability.
Cyclerion Therapeutics (NASDAQ:CYCN): Precision Neuropsychiatry Takes Shape
Cyclerion Therapeutics is advancing a differentiated approach to mental health with its lead program CYC-126, an investigational therapy for treatment-resistant depression (TRD). The company announced a strategic collaboration with Medsteer, a specialist in closed-loop anesthetic delivery systems that use real-time patient feedback.
CYC-126 integrates EEG monitoring, algorithm-guided dosing, and well-characterized anesthetic agents to create a personalized, precision-delivered treatment. Cyclerion is now progressing toward initiating a Phase 2 proof-of-concept study in the second half of 2026, with initial clinical data expected in 2027.
The collaboration strengthens Cyclerion's technical foundation by incorporating validated delivery technology already used across thousands of patients, potentially reducing execution risk in a therapeutic area with significant unmet need.
BullFrog AI (NASDAQ:BFRG): AI Uncovers Hidden Survival Gains in Pancreatic Cancer
BullFrog AI is gaining visibility ahead of the 2026 ASCO GI Symposium, where data derived from its bfLEAP® platform will be presented. Using post-hoc analysis of a Phase 3 pancreatic cancer trial, BullFrog AI identified patient subgroups showing nearly a threefold increase in mean survival between treatment and control arms.
The findings highlight how AI-driven clustering and biomarker identification can reveal treatment effect heterogeneity that traditional analyses may overlook. For drug developers, this approach offers a way to rescue shelved assets, refine patient stratification, and design more efficient trials, potentially reducing both cost and failure rates in oncology development.
For more information about Kraig Labs' spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information, please visit: www.kraiglabs.com
Contact [email protected] for Analyst Report coverage and other investor/public relations services.
About 24/7 Market News
24/7 Market News (247) is a leading market news platform for public companies. As a pioneer in digital media, 247 is dedicated to the swift distribution of financial market news and information. 247 takes great pride in creating innovative public relations campaigns that help clients reach the target audience.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247's Full Disclaimer https://www.247marketnews.com/disclaimer/.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
